<DOC>
	<DOCNO>NCT01057251</DOCNO>
	<brief_summary>The primary object study evaluate efficacy safety 6 week nebivolol monotherapy compare placebo patient systolic stage 2 hypertension .</brief_summary>
	<brief_title>Nebivolol Patients With Systolic Stage 2 Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>male female , 18 64 year age screen mean seat heart rate least 60 bpm diagnose systolic stage 2 hypertension unremarkable physical exam finding high risk due secondary hypertension former stage 3 hypertension JNC6 concurrent condition ( reno , cardiovascular , obesity , thyroid , etc ) currently take medication stop course study participate clinical trial member study center personnel document drug abuse contra indication beta blocker abnormal lab find poor compliance condition judge investigator suitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>Bystolic TM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Stage 2 Hypertension</keyword>
</DOC>